Company Overview and News

to your dashboard

Headline News

Genomic Health Cancer Diagnostic Tests Grow Amid Cost Woes

11h zacks
On Nov 15, we issued an updated research report on Genomic Health Inc (GHDX - Free Report) , a global cancer research company with focus on advanced molecular diagnostics. (35-0)

Medtronic Stock Dips on Preliminary Sales Drag, CRHF to Grow

12h zacks
On Nov 17, 2017, we issued an updated research report on medical device major, Medtronic plc (MDT - Free Report) . The stock carries a Zacks Rank #4 (Sell). (61-0)

Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength

2017-11-16 zacks
On Nov 16, we issued an updated research report on Luminex Corp (LMNX - Free Report) — a manufacturer and marketer of proprietary biological testing technologies with applications throughout the life sciences and diagnostics industry. (47-0)

LabCorp Reports New Use of Agilent's Cancer Diagnostic Test

2017-11-16 zacks
Laboratory Corporation of America Holdings (LH - Free Report) or LabCorp recently announced that Agilent’s Dako pathology division’s development — the PD-L1 IHC 28-8 pharmDx assay — is now available in the United States for new expanded use. Per LabCorp, this test has got the U.S. approval to be used as a complementary diagnostic with Bristol-Myers Squibb Company’s (BMY - Free Report) OPDIVO (nivolumab) for two new indications — metastatic urothelial carcinoma or bladder cancer and squamous cell carcinoma of the head and neck — respectively. (117-0)

Here's Why Investors Should Buy Myriad Genetics Right Now

2017-11-16 zacks
Myriad Genetics, Inc. (MYGN - Free Report) has rallied 12.2% over the last three months, ahead of the S&P 500’s 6.3% gain and also better than the broader industry’s decline of 4.6%. The stock has a market cap of $2.16 billion. (44-0)

Illumina Introduces NextSeq 550Dx, Updates Use of MiSeqDx

2017-11-16 zacks
Illumina, Inc. (ILMN - Free Report) recently introduced its second FDA-regulated and CE-IVD marked next-generation sequencing (NGS) system — NextSeq 550Dx. The instrument has been designed to deliver the power of high-throughput NGS to the clinical laboratory. (55-0)

Myriad Genetics' Latest Alliance to Boost GeneSight Reach

2017-11-15 zacks
Myriad Genetics, Inc.’s (MYGN - Free Report) wholly owned subsidiary Assurex Health recently formed an alliance with the Department of Veterans Affairs (VA) in PRIME Care (PRecision Medicine In MEntal Health Care) — a multi-center and national trial to evaluate the effectiveness of GeneSight test in improving health resultsfor veterans suffering from major depressive disorder (MDD). (83-0)

Haemonetics (HAE) Grows on Strong Plasma, Competition Rife

2017-11-15 zacks
On Nov 14, we issued an updated research report on Haemonetics Corporation (HAE - Free Report) . The company has been trading above the broader industry over the last month. The stock has gained 19.9% as against the broader industry’s 0.5% gain. The stock has also outperformed the S&P 500’s 1.2% gain. The stock currently carries a Zacks Rank #3 (Hold). (83-0)

Here's Why Investors Should Buy Luminex (LMNX) Right Now

2017-11-15 zacks
Luminex Corporation (LMNX - Free Report) has rallied 10.9% over the last three months, ahead of the S&P 500’s 4.8% gain and also better than the broader industry’s rise of 4.6%. The stock has a market cap of $937.5 million.The company’s current-year historical growth rate is also favorable at 53.1% as compared with 22.7% of the S&P 500 index and 17.6% of the broader industry. (83-0)

Quest Diagnostics, Clinical Genomics Ally, Oncology Strong

2017-11-14 zacks
Quest Diagnostics Inc. (DGX - Free Report) and Clinical Genomics, a major player in the field of colorectal cancer detection, jointly announced the FDA clearance of the latter’s InSure ONE. (30-0)

Weight Watchers (WTW) to Issue $500M Senior Notes Due 2025

2017-11-14 zacks
Weight Watchers International Inc. (WTW - Free Report) recently announced an offering of $500 million senior notes, due in 2025. The notes will be unsecured and will be guaranteed by the company's subsidiaries. The company intends to enter into a new $150-million revolving credit facility to refinance its existing one. (24-0)

Bio-Rad (BIO) Beats Earnings and Revenue Estimates in Q3

2017-11-13 zacks
Bio-Rad Laboratories, Inc. (BIO - Free Report) reported third-quarter 2017 earnings of 91 cents per share, a 46.8% surge from the year-ago figure. The bottom line also surpassed the Zacks Consensus Estimate of 33 cents by a wide margin. Notably, net income in the quarter was favorably impacted by higher sales and a significantly improved gross margin.  (36-0)

Medtronic Preliminary Sales Dip Y/Y, Hurricane Blow Lessens

2017-11-13 zacks
Medtronic plc (MDT - Free Report) announced dull preliminary sales results for second-quarter fiscal 2018. Preliminary worldwide revenues for the quarter dipped 4% year over year to $7.05 billion. The Zacks Consensus Estimate of $7.09 billion remains a tad higher than the reported preliminary revenue figure. (57-0)

BioTelemetry (BEAT) Q3 Earnings Miss, Revenues Meet Estimates

2017-11-13 zacks
BioTelemetry Inc. (BEAT - Free Report) reported third-quarter 2017 adjusted earnings of 16 cents per share, which widely missed the Zacks Consensus Estimate of 24 cents as well as the year-ago equivalent of 21 cents. (20-0)

Bruker's NANO Grows Strong, MERLIN Buyout Holds Promise

2017-11-10 zacks
On Nov 08, we issued an updated research report on Bruker Corporation (BRKR - Free Report) . The stock carries a Zacks Rank #3 (Hold). (13-0)

CUSIP: 716382106